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Abstract
Background:  Methylenetetrahydrofolate reductase (MTHFR) has a major impact on the
regulation of the folic acid pathway due to conversion of 5,10-methylenetetrahydrofolate
(methylene-THF) to 5-methyl-THF. Two common polymorphisms (677C>T and 1298A>C) in the
gene coding for MTHFR have been shown to reduce MTHFR enzyme activity and were associated
with the susceptibility to different disorders, including vascular disease, neural tube defects and
lymphoid malignancies. Studies on the role of these polymorphisms in the susceptibility to acute
lymphoblastic leukemia (ALL) led to discrepant results.
Methods: We retrospectively evaluated the association of the MTHFR 677C>T and 1298A>C
polymorphisms with pediatric ALL by genotyping a study sample of 443 ALL patients consecutively
enrolled onto the German multicenter trial ALL-BFM 2000 and 379 healthy controls. We
calculated odds ratios of MTHFR  genotypes based on the MTHFR  677C>T and 1298A>C
polymorphisms to examine if one or both of these polymorphisms are associated with pediatric
ALL.
Results: No significant associations between specific MTHFR variants or combinations of variants
and risk of ALL were observed neither in the total patient group nor in analyses stratified by
gender, age at diagnosis, DNA index, immunophenotype, or TEL/AML1 rearrangement.
Conclusion: Our findings suggest that the MTHFR 677C>T and 1298A>C gene variants do not
have a major influence on the susceptibility to pediatric ALL in the German population.
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Background
Methylenetetrahydrofolate reductase (MTHFR) has a
major impact on the regulation of the folic acid pathway
due to the conversion of 5,10-methylenetetrahydrofolate
(methylene-THF) to 5-methyl-THF. Two common non-
synonymous coding region polymorphisms (677C>T and
1298A>C) in the MTHFR  gene were shown to confer
reduced enzyme activity in in vitro assays leading to a
decreased pool of methyl-THF and the MTHFR variant
677C>T was associated with an increased risk of hyperho-
mocysteinemia, particularly in folate-deficient states [1-
4]. With regard to the MTHFR 677C>T polymorphism,
results from in vitro assays showed a decrease in enzyme
activity to 65% for the heterozygous and to 30% for the
homozygous state of the 677T variant [5]. For the
1298A>C polymorphism, enzyme activity in vitro is
decreased in homozygous variants and, to a lesser extent,
in heterozygotes compared with those homozygous for
the wild-type allele [6,7]. It is supposed that variants
(677TT/1298AA or 677CC/1298CC) of MTHFR increase
the level of methylene-THF leading to a subsequent reduc-
tion of uracil in DNA. The reduction of uracil decreases
the amount of misincorporations of uracil instead of thy-
midine into DNA. This may protect DNA from double-
strand breaks and, consequently, from chromosomal
alterations [1,8]. Furthermore,it is assumed that DNA
methylation via MTHFR is an important epigenetic feature
that modulates DNA methylation status through interac-
tion with folate status [1,9]. Consequently, MTHFR vari-
ants are discussed to influence disease processes and
several studies in the literature reported on reduced
MTHFR enzyme activity and the susceptibility to different
disorders, including vascular disease, neural tube defects
and lymphoid malignancies [1,2,5,7,8,10-13]. Lymphoid
malignancies arise as a consequence of point mutations,
chromosomal rearrangements (e.g., chromosomal trans-
locations), and epigenetic alterations in hematopoietic
cells making the variant MTHFR an interesting candidate
gene for studies on leukemogenesis [14]. However, espe-
cially with regard to susceptibility to acute lymphoblastic
leukemia (ALL), previous studies led to discrepant results.
Although both variants 677T and 1298C have been
reported to decrease susceptibility to ALL in children and
adults [8,10,11,13], other investigators did not support
such associations [15,16]. Moreover, the protective effect
of MTHFR variants was present only in children before
folic acid supplement in pregnancy has been recom-
mended [17]. These results suggest a role for gene-envi-
ronment interactions in the association of MTHFR with
ALL.
In the present study, we analyzed the association of
MTHFR variants with pediatric ALL in a German study
sample including 443 ALL patients and 379 healthy
controls.
Methods
Patients and controls
The present study used data and specimens derived from
patients of the ongoing ALL-BFM 2000 trial that is con-
ducted by the Berlin-Frankfurt-Münster (BFM) study
group and enrolls pediatric patients from 1 year up to 18
years of age with a diagnosis of ALL from 84 different
treatment centers in Germany, Austria, and Switzerland
[18]. From July 1999 until the end of February 2001, 497
patients of up to 18 years of age were enrolled onto the
clinical trial after informed consent was obtained from the
parents or legal guardians. The diagnosis was established
in our central reference laboratory by morphological FAB
criteria and cytochemistry when at least 25% lymphob-
lasts were present in the bone marrow, or when blasts
were present in the peripheral blood. The assessments of
immunophenotype, cellular DNA content, and positivity
for TEL/AML1, BCR/ABL, and MLL/AF4 fusion genes were
done as described previously [19,20]. Patients were
included into the present study, when biological material
was available at the study center leading to a study popu-
lation of 443 patients (89.7% of the entire study popula-
tion) who with regard to clinical characteristics did not
significantly differ from the entire study population of
497 patients. Controls (n = 379) consisted of blood sam-
ples from healthy blood donors (aged between 18–68
years), with no history of malignant neoplastic disease.
They were derived through the Department of Transfusion
Medicine, Hannover Medical School, Hannover, Ger-
many, and the Clinic Center of Bremen, Bremen, Ger-
many. Individuals included in the present study were of
Caucasian descent. The study was approved by the local
ethics committee.
Genotyping
DNA was extracted from peripheral blood or bone mar-
row samples by using the QIAamp DNA Blood Midi Kit
(Qiagen GmbH, Hilden, Germany). Depending on avail-
ability, either tumor material or remission samples were
used. Analyses of MTHFR variants were performed on a
LightCycler® instrument (Roche Diagnostics, Mannheim
Germany) using a commercial real-time assay (Artus Bio-
tech, Hamburg, Germany) according to the manufac-
turer's instructions. Both variants MTHFR  677C>T and
1298A>C were analyzed by simultaneous amplification in
a single real-time PCR run. Melting curve analyses were
performed for both variants after PCR amplification. No
differences in the distribution of MTHFR variants were
observed between tumor and remission samples (data not
shown).
Statistical analysis
The association of MTHFR variants with risk of disease
was examined by use of unconditional logistic regression
analysis to calculate odds ratios (OR) and their 95%BMC Medical Genetics 2005, 6:23 http://www.biomedcentral.com/1471-2350/6/23
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confidence intervals (CI). P values of <0.05 were consid-
ered statistically significant. The MTHFR variant was used
as a categorical variable in these analyses. The expected
frequency of MTHFR variants in controls was analyzed by
the Hardy-Weinberg equilibrium test. The SPSS statistical
package (SPSS Inc., Chicago, IL) was used for computer-
ized calculations.
Results and Discussion
Table 1 shows the distribution of clinical characteristics in
the study sample of 443 childhood ALL patients from
ALL-BFM 2000. Distribution of MTHFR variants within
patients and controls are summarized in Table 2. In our
control population of 379 healthy individuals the fre-
quencies of MTHFR variants 677C>T and 1298A>C were
in Hardy-Weinberg equilibrium (677: χ 2 = 1.81, 1298: χ 2
= 0.05; P > 0.05) and demonstrated strong linkage dise-
quilibrium (P < 0.001). None of the haplotypes was
observed more frequently in the ALL group (Tab. 2).
MTHFR variants that were previously reported to confer a
reduced risk of ALL were similarly distributed in the
patient and control group. The frequency of the variant
MTHFR 677T was 0.314 in controls and 0.333 in children
with ALL. Ogino et al. reported a frequency of 0.320 in a
meta-analysis including 5389 individuals [21]. There was
also no significant different distribution of the MTHFR
1298C variant between our patient and control groups.
The 1298C variant occurs with a frequency of 0.367 in
controls and 0.314 in patients with ALL. Ogino et al.
reported 0.308 in their meta-analysis [21]. The calculated
OR and their respective 95% CI are also shown in Table 2.
No significant associations between specific MTHFR vari-
ants or combinations of MTHFR variants and risk of ALL
were observed neither in the total patient group nor in
analyses stratified by gender, age at diagnosis, DNA index,
immunophenotype, or TEL/AML1 rearrangement (strati-
fied analyses not shown; strata as shown in Table 1).
With regard to ALL, our results are in contrast to previous
findings and do not support the assumption that higher
methylene-THF levels due to MTHFR variants lead to a
decreased risk of ALL in our study population
[8,10,11,13]. There are different explanations for these
diverging results. The present study included pediatric
patients from Germany. The above mentioned studies
included adult patients from United Kingdom [8] and
Italy [13] but also pediatric patients from United King-
dom [10] or Brazil [11]. These latter two studies on the
MTHFR 677C>T and 1298A>C polymorphisms in child-
hood ALL included patients diagnosed between 1992–
1998 and 1991–2000, respectively, while our study
included pediatric ALL patients diagnosed after July 1999.
Thus, probably a large proportion of patients analyzed in
the studies by Wiemels et al. [10] and Franco et al. [11]
were born before folic acid supplementation in pregnancy
was recommended. In a Canadian study, Krajinovic et al.
reported that the protective effect of MTHFR variants was
accentuated and present only in children born before
1996 [17]. This may explain the diverging results with
regard to pediatric ALL and is further supported by a
recent study of Balta and colleagues from Turkey, where in
142 pediatric ALL patients diagnosed between February
2000 and February 2002, no significant association
between the MTHFR 677C>T polymorphism and ALL was
detected [16]. However, the impact of folate metabolism
on the risk of ALL may also vary from population to pop-
ulation because of additional gene-environment and
gene-gene interactions. For example, in our study popula-
tion we cannot control for differences in folate status as
we have not collected information on dietary intake.
Thus, a potentially existing association of MTHFR variants
and ALL may be masked by the inability to control for the
individual folate status in our study population. Further-
Table 1: Clinical characteristics of patients from trial ALL-BFM 
2000
Patients ALL-BFM 2000 (n = 443)
Number of subjects (%)
Gender
Male 268 (60.5)
Female 175 (39.5)
Age at diagnosis (years)
< 1 -
1-< 6 264 (59.6)
6-< 10 80 (18.1)
≥  10 99 (22.3)
DNA indexa
< 1.16 258 (58.2)
≥  1.16 48 (10.8)
no result 137 (30.9)
TEL/AML1 pos. 90 (20.3)
neg. 313 (70.7)
unknown 40 (9.0)
BCR/ABL pos. 9 (2.0)
neg. 412 (93.0)
unknown 22 (5.0)
MLL/AF4 pos. 1 (0.2)
neg. 394 (88.9)
unknown 48 (9.9)
Immunophenotype
Precursor B 344 (77.7)
T8 1  ( 1 8 . 3 )
Bipenotypic 4 (0.9)
Unknown 14 (3.2)
aRatio of DNA content of leukemic G0/G1 cells to normal diploid 
lymphocytes.BMC Medical Genetics 2005, 6:23 http://www.biomedcentral.com/1471-2350/6/23
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more, we cannot exclude potential gene-gene interactions.
As several polymorphic key enzymes are involved in folate
metabolism, a more comprehensive approach would
clearly yield more precise estimates of the association of
folate metabolism with risk of ALL. As an additional
explanation for diverging results, specifically in subgroups
with chromosomal translocations, the potential impor-
tance of parental variants and folate status with respect to
an in utero pathogenesis of ALL (e.g., MLL/AF4 and TEL/
AML1 fusion gene-positive ALL) should be considered
[22]. Lastly, our results may simply be due to chance and
small patient numbers. However, with regard to sample
size, our study exceeds most other studies reported in the
literature, so far. In conclusion, our findings suggest that
the MTFHR gene variants analyzed here do not have a
major influence on the susceptibility to pediatric ALL in
the German population. However, potential effects in rare
specific ALL subgroups cannot be excluded.
Conclusion
We retrospectively evaluated the association of the
MTHFR  677C>T and 1298A>C polymorphisms with
childhood ALL by analyzing a study sample of 443 ALL
patients consecutively enrolled onto the German multi-
center trial ALL-BFM 2000 and 379 healthy controls. No
significant associations between specific MTHFR variants
or combinations of MTHFR variants and risk of ALL were
observed neither in the total patient group nor in analyses
stratified by gender, age at diagnosis, DNA index, immu-
nophenotype, or TEL/AML1 rearrangement. Our findings
suggest that the MTHFR 677C>T and 1298A>C gene vari-
ants do not have a major influence on the susceptibility to
pediatric ALL in the German population.
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